Breaking New Ground in Cervical Metastatic Carcinoma of Unknown Primary: Neoadjuvant Immunochemotherapy’s Pathologic Regression and Survival Advantage

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Annals of Surgical Oncology

• Publication date

  2025-11-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1245/s10434-025-18739-yPMID 41299003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach

  2025cited by this paper
• Imaging of extranodal extension: why is it important in head and neck cancer?

  2025cited by this paper
• Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.

  2025cited by this paper
• Oncologic outcomes following neoadjuvant immunochemotherapy in locally advanced oral squamous cell carcinoma

  2025cited by this paper
• Neoadjuvant immunochemotherapy versus neoadjuvant immunoradiotherapy in locally advanced oral squamous cell carcinoma

  2025cited by this paper
• Evaluation of Efficacy of Neoadjuvant Immunochemotherapy for Cervical Metastatic Squamous Cell Carcinoma of Unknown Primary

  2025cited by this paper
• Head and Neck Cancer of Unknown Primary: A Surgical Perspective.

  2025cited by this paper
• Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer

  2024cited by this paper
• Survival outcomes in head and neck squamous cell carcinoma of unknown primary: A national cohort study

  2024cited by this paper
• Neoadjuvant chemoimmunotherapy in resectable locally advanced oral squamous cell carcinoma: a single-center retrospective cohort study

  2024cited by this paper
• The evolution of molecular management of carcinoma of unknown primary

  2024cited by this paper
• Effectiveness of surgery and chemotherapy with immune checkpoint inhibitor for cardiac metastatic squamous cell carcinoma of unknown primary.

  2024cited by this paper
• Low Skeletal Muscle Mass: A Strong Predictive Factor for Surgical Complications After Free Forearm Flap Reconstruction in Oral Cancer Patients

  2024cited by this paper
• Management of head and neck cancer of unknown primary: A phase IV study by DAHANCA.

  2024cited by this paper
• Impacts of additional cycles of neoadjuvant immunotherapy on surgery in non‐small‐cell lung cancer

  2023cited by this paper
• Clinical practice guidelines for management of head and neck squamous cell carcinoma of unknown primary: an AGREE II appraisal

  2023cited by this paper
• Does the number of cycles of neoadjuvant therapy affect the efficacy of neoadjuvant chemoimmunotherapy for non‐small cell lung cancer in locally advanced stage? Retrospective experience based on a single center

  2023influential reference
• Combined Immunotherapy and Tyrosine Kinase Inhibitor Treatment for Metastatic Renal Cell Carcinoma With Unknown Primary Origin: A Report of Two Cases and Literature Review

  2023cited by this paper
• Carcinoma of unknown primary (CUP): an update for histopathologists

  2023cited by this paper
• Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.

  2023cited by this paper
• Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.

  2023cited by this paper
• Comparison of PD-L1 expression in squamous cell cancer of unknown primary and oropharyngeal squamous cell carcinoma

  2022cited by this paper
• Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.

  2022cited by this paper
• Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival

  2022cited by this paper
• Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial

  2022cited by this paper
• The prognostic role of radiotherapy and radiotherapy target in cervical lymph node metastatic squamous cell carcinoma with unknown primary: a retrospective study

  2021cited by this paper
• iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

  2017influential reference

• No citing papers are available for this paper.